Polyclonal Antibody Production
Liselo has the capacity to manufacture polyclonal IgY antibodies against a very broad range of target antigens. The Liselo QBP is a platform that delivers high-capacity therapeutic antibody production at an affordable cost, utilizing an avian biopharming strategy. Liselo has geared this platform to be able to respond rapidly to potential outbreaks of emerging and re-emerging zoonotic diseases.
Customer-supplied antigens are used to generate custom polyclonal antibodies within 6-12 weeks, in quantities ranging from 100mg to 10g.
Plant-made recombinant proteins
Liselo Biologic’s GMP capacity for the production of recombinant proteins in N. benthamiana is based in Lesotho. The facility currently produces biologics for export to North American markets, for human therapeutics applications. cGMP capacity is currently being expanded at the facility, for a range of contracted customers, primarily for animal vaccine manufacture.